US Patent 11286264 Macrocyclic compounds and uses thereof
Patent 11286264 was granted and assigned to Turning Point Therapeutics on March, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 15 May, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 4 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 16 Oct, 2023
Golden AI
Edits made to:
Infobox (+10 properties)
Infobox
Patent Inventor Names
Dayong Zhai0
Evan W. Rogers0
Han Zhang0
Jane Ung0
Jeffrey Whitten0
Jing Liu0
Jingrong Jean Cui0
Wei Deng0
Xin Zhang0
Zhongdong Huang0
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 27 Apr, 2023
Golden AI
Infobox
Patent Citations
Edits on 1 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
112862640
Date of Patent
March 29, 2022
0Patent Application Number
166342890
Date Filed
July 26, 2018
0Official Website
Patent Citations
Patent Primary Examiner
CPC Code
Edits on 25 Sep, 2022
Golden AI
Infobox
Patent Citations
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 30 Mar, 2022
Golden AI
Edits made to:
Infobox (+16 properties)
Article (+211 characters)
US Patent 11286264 Macrocyclic compounds and uses thereof
Article
The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11286264
Date of patent
March 29, 2022
Patent application number
16634289
Date Filed
July 26, 2018
Patent citations
Patent primary examiner
Find more entities like US Patent 11286264 Macrocyclic compounds and uses thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
